• Publications
  • Influence
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma.
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
TLDR
The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
TLDR
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
TLDR
Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
TLDR
In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
TLDR
Continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.
...
1
2
3
4
5
...